Literature DB >> 12719774

The preparation and phospholipid binding property of the C2 domain of human factor VIII.

Kazuya Takeshima1, Christina Smith, Jonathan Tait, Kazuo Fujikawa.   

Abstract

The C2 domain of human factor VIII was expressed in a yeast secretion system and its binding properties were studied. A cDNA coding the C2 domain sequence of human factor VIII with a N-terminal six amino acids extension (C-C2) was constructed, transformed into Pichia pastoris cells and expressed. The product was purified by ammonium sulfate fractionation and anion exchange chromatography. It emerged as a single peak from both ion exchange and gel filtration columns, indicating C-C2 is a homogenous monomer. The binding activity of C-C2 to phosphatidylserine-containing phospholipid vesicles was measured by competitive binding with annexin V. The values of IC50 were approximately 70nM for both factor VIII and its light chain, but were about 7000nM for C-C2. These results indicated C-C2 has 100-fold less binding affinity than factor VIII or the light chain. Direct binding to solidified phosphatidyl-serine-containing phospholipids also showed that C-C2 has approximately 50-fold less binding affinity than does the light chain. C-C2 poorly inhibited Xase activity. These results together clearly show that the C2 domain alone does not have full membrane binding activity, and suggest that the other light chain domains, A3 and/or C1, are also involved in the phospholipid binding activity of factor VIII.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12719774

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.

Authors:  Tie Chi Lei; David W Scott
Journal:  Blood       Date:  2005-03-15       Impact factor: 22.113

2.  Membrane-binding properties of the Factor VIII C2 domain.

Authors:  Valerie A Novakovic; David B Cullinan; Hironao Wakabayashi; Philip J Fay; James D Baleja; Gary E Gilbert
Journal:  Biochem J       Date:  2011-04-01       Impact factor: 3.857

3.  The factor VIII C1 domain contributes to platelet binding.

Authors:  Ting-Chang Hsu; Kathleen P Pratt; Arthur R Thompson
Journal:  Blood       Date:  2007-10-04       Impact factor: 22.113

4.  The tertiary structure and domain organization of coagulation factor VIII.

Authors:  Betty W Shen; Paul Clint Spiegel; Chong-Hwan Chang; Jae-Wook Huh; Jung-Sik Lee; Jeanman Kim; Young-Ho Kim; Barry L Stoddard
Journal:  Blood       Date:  2007-10-26       Impact factor: 22.113

5.  Identification of plasmin-interactive sites in the light chain of factor VIII responsible for proteolytic cleavage at Lys36.

Authors:  Keiji Nogami; Katsumi Nishiya; Evgueni L Saenko; Masahiro Takeyama; Kenichi Ogiwara; Akira Yoshioka; Midori Shima
Journal:  J Biol Chem       Date:  2009-01-06       Impact factor: 5.157

6.  Crystal structure of the bovine lactadherin C2 domain, a membrane binding motif, shows similarity to the C2 domains of factor V and factor VIII.

Authors:  Lin Lin; Qing Huai; Mingdong Huang; Bruce Furie; Barbara C Furie
Journal:  J Mol Biol       Date:  2007-05-25       Impact factor: 5.469

7.  Six amino acid residues in a 1200 Å2 interface mediate binding of factor VIII to an IgG4κ inhibitory antibody.

Authors:  Jasper C Lin; Ruth A Ettinger; Jason T Schuman; Ai-Hong Zhang; Muhammad Wamiq-Adhami; Phuong-Cac T Nguyen; Shelley M Nakaya-Fletcher; Komal Puranik; Arthur R Thompson; Kathleen P Pratt
Journal:  PLoS One       Date:  2015-01-23       Impact factor: 3.240

8.  SAXS analysis of the intrinsic tenase complex bound to a lipid nanodisc highlights intermolecular contacts between factors VIIIa/IXa.

Authors:  Kenneth C Childers; Shaun C Peters; Pete Lollar; Harold Trent Spencer; Christopher B Doering; Paul C Spiegel
Journal:  Blood Adv       Date:  2022-06-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.